Michael Horberg to Reverse Transcriptase Inhibitors
This is a "connection" page, showing publications Michael Horberg has written about Reverse Transcriptase Inhibitors.
Connection Strength
0.895
-
Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. HIV Clin Trials. 2008 Nov-Dec; 9(6):367-74.
Score: 0.317
-
Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):393-398.
Score: 0.236
-
Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 04; 23(4):e25484.
Score: 0.175
-
Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012 Nov 13; 26(17):2223-31.
Score: 0.105
-
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis. 2005 Aug 01; 192(3):456-65.
Score: 0.063